OGEN - Oragenics Inc Stock Price, Fair Value and News

2.33USD+0.69 (+42.07%)Delayed

Market Summary

USD2.33+0.69

Delayed

42.07%

OGEN Stock Price

View Fullscreen

OGEN RSI Chart

OGEN Valuation

Market Cap

10.4M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

277.27

EV/EBITDA

-0.41

Price/Free Cashflow

-1.27

OGEN Price/Sales (Trailing)

OGEN Profitability

EBT Margin

-53811.74%

Return on Equity

-771.8%

Return on Assets

-573.35%

Free Cashflow Yield

-78.99%

OGEN Fundamentals

OGEN Revenue

Revenue (TTM)

37.7K

Rev. Growth (Yr)

-91.32%

Rev. Growth (Qtr)

-43.28%

OGEN Earnings

Earnings (TTM)

-20.3M

Earnings Growth (Yr)

13.85%

Earnings Growth (Qtr)

80.77%

Breaking Down OGEN Revenue

Last 7 days

26.6%

Last 30 days

115.7%

Last 90 days

-35.6%

Trailing 12 Months

-22.1%

How does OGEN drawdown profile look like?

OGEN Financial Health

Current Ratio

1.36

OGEN Investor Care

Shares Dilution (1Y)

121.31%

Diluted EPS (TTM)

-8.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	133.5K	116.2K	37.7K	37.7K
2022	98.1K	109.3K	120.4K	131.5K
2021	0	0	0	87.0K
2020	827.5K	580.7K	333.8K	0
2016	1.1M	0	0	0
2015	1.1M	1.0M	1.2M	1.2M
2014	1.1M	1.2M	1.2M	939.9K
2013	1.1M	1.0M	1.0M	1.0M
2012	1.5M	1.4M	1.3M	1.3M
2011	1.3M	1.4M	1.4M	1.4M
2010	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Oragenics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 30, 2023	telling fred	sold	-12,488	3.5681	-3,500	-
Aug 08, 2023	koski robert c	acquired	-	-	25,000	-
Aug 08, 2023	huffman janet	acquired	-	-	15,000	cfo, secretary and treasurer
Aug 08, 2023	murphy kimberly m	acquired	-	-	25,000	ceo and president
Aug 08, 2023	telling fred	acquired	-	-	25,000	-
Aug 08, 2023	dunton alan w	acquired	-	-	25,000	-
Aug 08, 2023	pope charles l	acquired	-	-	25,000	-
Dec 30, 2022	koski robert c	sold	-4,468	0.1055	-42,357	-
Dec 29, 2022	koski robert c	sold	-3,884	0.106	-36,648	-

Which funds bought or sold OGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	sold off	-100	-23.00	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-473	163	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	210	-2,172	8,444	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	sold off	-100	-6.00	-	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	265	-6,000	81,000	-%
May 13, 2024	FMR LLC	reduced	-96.69	-14,488	124	-%
May 13, 2024	Team Financial Group, LLC	sold off	-100	-6.00	-	-%
May 13, 2024	UBS Group AG	sold off	-100	-186	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	1.57	-82,475	28,971	-%

Are Funds Buying or Selling OGEN?

Are funds buying OGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OGEN

No. of Funds

Unveiling Oragenics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	lind global fund ii lp	5.9%	265,000	SC 13G
Feb 12, 2024	odyssey health, inc.	16.6%	511,308	SC 13D
Jan 29, 2021	intracoastal capital, llc	1.6%	1,491,667	SC 13G/A
Jan 26, 2021	hernandez joseph	0%	0	SC 13D/A
Oct 08, 2020	kirk randal j	0.4%	230,792	SC 13D/A
May 15, 2020	hernandez joseph	16.6%	9,200,000	SC 13D
Mar 02, 2020	kirk randal j	9.9%	4,612,166	SC 13D/A
Feb 14, 2020	anson funds management lp	4.9%	2,422,511	SC 13G/A
Feb 11, 2020	intracoastal capital, llc	6.7%	3,333,334	SC 13G/A
Feb 10, 2020	cvi investments, inc.	4.9%	2,422,511	SC 13G/A

Recent SEC filings of Oragenics Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 16, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 22, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report
Mar 06, 2024	SC 13G	Major Ownership Report
Mar 01, 2024	8-K	Current Report

Peers (Alternatives to Oragenics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Oragenics Inc News

Latest updates

Oragenics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q3	2020Q2	2020Q1	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2
Revenue	-	-	-	7,466	13,163	17,024	-	86,047	30,391	15,083	64,518	113,953	163,388	212,823	262,258	240,234	329,795	242,038	363,774	220,504	201,010	303,752
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	172,304	-97,888	-	-	195,777	129,983	127,299	178,147
Operating Expenses	-80.8%	2,460,103	12,796,324	2,101,912	3,122,481	2,921,839	2,299,412	3,992,566	3,634,856	4,625,210	2,388,102	4,508,367	12,352,306	5,231,762	-	-	-	-	-	-	-	-
S&GA Expenses	-100.0%	-	1,754,343	1,332,562	1,115,785	1,249,263	887,734	1,215,498	1,044,334	1,331,549	1,077,758	1,010,006	808,333	1,519,083	-	-	-	-	-	-	-	-
R&D Expenses	-94.0%	663,414	11,041,982	769,350	2,006,696	1,672,576	1,411,923	2,777,068	2,590,032	3,293,661	1,310,344	3,498,361	11,543,973	3,712,679	-	-	-	-	-	-	-	-
EBITDA Margin	1.9%	-536	-547	-267	-102	-93.51	-108	-118	-135	-153	-179	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-42.1%	7,085	12,231	14,170	843	3,347	5,813	5,228	816	3,246	5,102	3,885	885	1,708	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	80.8%	-2,450,833	-12,747,429	-2,012,885	-3,050,586	-2,844,837	-2,237,740	-3,870,113	-3,589,543	-4,590,993	-2,292,576	-4,496,560	-12,337,296	-5,187,760	-	-	-	-	-	-	-	-
EBT Margin	1.9%	-538	-548	-269	-103	-93.98	-108	-119	-135	-153	-180	-	-	-	-	-	-	-	-	-	-	-
Net Income	80.8%	-2,450,833	-12,747,429	-2,012,885	-3,050,586	-2,844,837	-2,237,740	-3,870,113	-3,589,543	-4,590,993	-2,292,576	-4,496,560	-12,337,296	-5,187,760	-	-	-	-	-	-	-	-
Net Income Margin	1.9%	-538	-548	-269	-103	-93.98	-108	-119	-135	-153	-180	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-177.4%	-3,067,687	-1,105,983	-1,506,450	-2,580,066	-2,112,133	-2,436,274	-3,812,924	-3,382,805	-5,723,999	-2,504,347	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-28.8%	4.00	5.00	8.00	8.00	12.00	15.00	17.00	20.00	24.00	28.00	31.00	35.00	37.00	19.00	11.00	11.00	16.00	20.00	24.00	27.00	31.00
Current Assets	-36.8%	2.00	4.00	8.00	8.00	12.00	14.00	17.00	20.00	23.00	28.00	31.00	35.00	37.00	18.00	11.00	10.00	15.00	19.00	23.00	26.00	31.00
Cash Equivalents	-40.5%	2.00	3.00	6.00	6.00	9.00	11.00	14.00	18.00	21.00	27.00	30.00	35.00	37.00	18.00	10.00	10.00	14.00	18.00	22.00	26.00	29.00
Net PPE	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-49.5%	1.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	-100.0%	-	2.00	1.00	1.00	2.00	2.00	2.00	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00
Shareholder's Equity	-17.1%	3.00	3.00	6.00	7.00	10.00	13.00	15.00	19.00	22.00	26.00	29.00	33.00	36.00	17.00	10.00	9.00	13.00	17.00	21.00	24.00	29.00
Retained Earnings	-1.2%	-208	-206	-193	-191	-188	-185	-183	-179	-175	-171	-168	-164	-160	-154	-150	-145	-133	-127	-123	-119	-115
Additional Paid-In Capital	0.9%	210	208	198	197	197	197	197	195	195	195	195	195	194	164	152	147	139	138	138	138	138
Shares Outstanding	45.4%	4.00	3.00	3.00	2.00	-	117	-	116	-	2.00	-	116	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	7.00	-	-	-	42.00	-	-	-	81.00	-	-	-	37.00	-	-	-	22.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-177.9%	-3,064	-1,102	-1,503	-2,576	-2,108	-2,432	-3,775	-3,382	-5,636	-2,484	-4,579	-2,078	-4,327	-3,631	-4,665	-4,832	-3,822	-3,936	-3,377	-3,487	-2,210
Share Based Compensation	-87.0%	69.00	532	279	64.00	80.00	-798.50*	279	279	90.00	232	101	231	1,124	274	195	157	865	10.00	232	165	146
Cashflow From Investing	100.0%	-	-1,000	-	-	-	-3.44	-37.03	-	-75.05	-19.75	-	-	-	-	-	-	-	-13.86	-	-	-
Cashflow From Financing	1015.1%	1,653	-180	732	-107	-159	-87.99	-103	-122	-181	-178	-21.91	152	23,189	11,228	5,080	90.00	-73.02	-73.56	-50.00	-130	11,351

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OGEN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Grant revenue		$ 17,024
Operating expenses:
Research and development	663,414	1,672,576
General and administrative	1,796,689	1,249,263
Total operating expenses	2,460,103	2,921,839
Loss from operations	(2,460,103)	(2,904,815)
Other income (expense):
Interest income	19,235	62,201
Interest expense	(7,085)	(3,347)
Other income		1,124
Foreign currency exchange, net	(2,880)
Total other income, net	9,270	59,978
Loss before income taxes	(2,450,833)	(2,844,837)
Income tax benefit
Net loss	$ (2,450,833)	$ (2,844,837)
Basic net loss per share	$ (0.70)	$ (1.41)
Diluted net loss per share	$ (0.70)	$ (1.41)
Shares used to compute basic net loss per share	3,496,078	2,204,766
Shares used to compute diluted net loss per share	3,496,078	2,204,766

OGEN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,071,989	$ 3,483,501
Prepaid expenses and other current assets	371,212	382,273
Total current assets	2,443,201	3,865,774
Prepaid research and development expense	1,090,750	1,090,750
Operating lease right-of-use assets		9,811
Total assets	3,533,951	4,966,335
Current liabilities:
Accounts payable and accrued expenses	781,846	1,475,667
Short-term notes payable	126,840	312,703
Operating lease liabilities - Current		9,811
Total liabilities	908,686	1,798,181
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000 and 5,417,000 Series A shares, 4,050,000 and 4,050,000 Series B shares, -0- and -0- Series C shares, 7,488,692 and 7,488,692 Series F shares outstanding at March 31, 2024 and December 31, 2023, respectively	1,592,723	1,592,723
Common stock, $0.001 par value; 350,000,000 shares authorized and 4,480,693 and 3,080,693 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	4,480	3,081
Additional paid-in capital	209,697,149	207,790,604
Accumulated Deficit	(208,669,087)	(206,218,254)
Total shareholders’ equity	2,625,265	3,168,154
Total liabilities and shareholders’ equity	$ 3,533,951	$ 4,966,335

About Oragenics Inc

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

CEO	Ms. Kimberly M. Murphy
WEBSITE	oragenics.com
INDUSTRY	Biotechnology
EMPLOYEES	6

Oragenics Inc Frequently Asked Questions

What is the ticker symbol for Oragenics Inc? What does OGEN stand for in stocks?

OGEN is the stock ticker symbol of Oragenics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oragenics Inc (OGEN)?

As of Fri May 17 2024, market cap of Oragenics Inc is 10.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OGEN stock?

You can check OGEN's fair value in chart for subscribers.

What is the fair value of OGEN stock?

You can check OGEN's fair value in chart for subscribers. The fair value of Oragenics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Oragenics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Oragenics Inc a good stock to buy?

The fair value guage provides a quick view whether OGEN is over valued or under valued. Whether Oragenics Inc is cheap or expensive depends on the assumptions which impact Oragenics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OGEN.

What is Oragenics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OGEN's PE ratio (Price to Earnings) is -0.52 and Price to Sales (PS) ratio is 277.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Oragenics Inc's stock?

In the past 10 years, Oragenics Inc has provided -0.46 (multiply by 100 for percentage) rate of return.